Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Cardiac disorders – page 22

  • 481 clinical trials
  • 225 recruiting
  • 172 conditions
  • 28 countries

Conditions in this area

172 conditions with trials, the busiest first

Atrial fibrillation55Cardiac failure42Coronary artery disease37Acute myocardial infarction30Cardiac amyloidosis29Acute coronary syndrome21Cardiac arrest19Cardiac failure chronic17Cardiovascular disorder16Heart failure with reduced ejection fraction16Hypertrophic cardiomyopathy16Cardiac failure acute14Glycogen storage disease type II14Heart failure with preserved ejection fraction13Myocardial infarction13Cardiomyopathy11Myocardial ischaemia11Cardiogenic shock10Chronic coronary syndrome10Dilated cardiomyopathy9Myocarditis9Aortic valve stenosis7Chronic kidney disease6Trisomy 216+148

Clinical trials in Cardiac disorders

481 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

481 clinical trials

Endocarditis bacterial

Not yet recruiting

Dalbavancin versus standard drug combination for treatment of infective endocarditis caused by Gram‑positive cocci in adult patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Cardiovascular disorder

Not yet recruiting

Rosuvastatin zinc 20 mg for patients with cardiovascular disease and statin intolerance: a trial comparing continuation after a 36‑week N‑of‑1 self‑assessment versus standard care

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rosuvastatin Zinc
  • Sponsor:Copenhagen University Hospital

Hypertrophic cardiomyopathy

Not yet recruiting

Study of Short‑and Long‑Term Hemodynamic and Physiological Effects of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Region Skane

Atrial fibrillation

Not yet recruiting

Colchicine after Electrocardioversion to Prevent Recurrence of Atrial Fibrillation in Adult Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitaetsspital Basel

Cardiac failure

Not yet recruiting

Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetazolamide
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Heart disease congenital

Not yet recruiting

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Chiesi Farmaceutici S.p.A.

Coronary artery disease

Not yet recruiting

Prognostic H2[15O] PET Imaging Study in Patients with Coronary Artery Disease Using O15‑Water, Adenosine and Regadenoson

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Vaestra Goetalandsregionen

Cardiac failure

Not yet recruiting

Effect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Pulmonary arterial hypertension+1

Not yet recruiting

Vasopressin Versus Norepinephrine for Patients with Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Fondation Hopital Saint Joseph

Coronary artery disease

Not yet recruiting

A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

Type 2 diabetes mellitus+2

Not yet recruiting

Effect of semaglutide, acetylsalicylic acid, and clopidogrel on blood clotting in patients with diabetes or overweight with cardiovascular disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Cardiac failure+1

Not yet recruiting

A feasibility study of dapagliflozin for elderly patients hospitalized with chronic heart failure.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:Centre Hospitalier Regional Universitaire

Substances studied in this area

The therapies tested most often in Cardiac disorders trials.

Acetylsalicylic Acid44 clinical trialsClopidogrel30 clinical trialsTicagrelor27 clinical trialsSodium Chloride25 clinical trialsDapagliflozin22 clinical trialsApixaban21 clinical trialsEmpagliflozin20 clinical trialsRivaroxaban19 clinical trialsPrasugrel18 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.